Pfizer Inc. has announced plans to focus on developing its oral candidate danuglipron as a treatment for obesity and type 2 diabetes. This breakthrough comes after Pfizer officially discontinued development of a second candidate called lotiglipron.
The pharmaceutical giant has completely enrolled a Phase 2b study of danuglipron, and plans to finalize Phase 3 trial origins by the end of 2023. Pfizer’s Chief Scientific Officer William Sessa called the drug a prime candidate for differentiation based on profile, with full receptor agonism that could translate to robust efficacy.
Data published in the Journal of the American Medical Association Network Open from the Phase 2 trial of danuglipron revealed a significant drop of 4.17 kg of body weight over 16 weeks.
In contrast, the decision to discontinue development of lotiglipron was made after Pfizer found unusually high levels of transaminases from their Phase 1 study.
Though the company’s stock has dropped by 25% this year, the development of danuglipron has provided renewed hope as Pfizer continues to make progress in its fight against obesity and type 2 diabetes.